Loading
A phase 2 trial of SHR-A2102, Bevacizumab and Osimertinib in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors is a phase 2 interventional study registered as NCT06895928 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 400 participants planned, started 2025-03-28 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-A2102, Bevacizumab Injection, Adebelimab Injection, Ametinib Mesylate Tablets and Osimertinib Mesylate Tablets.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/